Screen Reader Access
Dr. Gurleen Kour
Scientist
Pharmacology Division
CSIR – Indian Institute of Integrative Medicine,Canal Road, Jammu – 180001
Email: gurleen[dot]kour[at]iiim[dot]res[dot]in
Bio Sketch
| Dr.Kour is currently working in the areas of inflammatory and metabolic disorders with the focus to explore natural compounds and their derivatives for their anti-inflammatory, anti-rheumatic and anti-obesity potential. In the area of pharmacology she has explored the combination of natural anti-inflammatory agents with first-line disease modifying anti-rheumatic drug (DMARDs). Her present research focuses on the combination of standard DMARDs with phytochemicals that have shown synergistic therapeutic effects while decreasing the toxic repercussions of current RA therapy. Furthermore, she has also worked on the preclinical drug development including the in vitro and in vivo assessment of ADME and pharmacokinetic properties for lead selection and lead optimization. Her current research focus is to develop natural product driven drug candidates in the area of rheumatoid arthritis and obesity. |
Education
| Degree | Subjects | University | Qualifying Year |
| Postdoctorate | Life Sciences | University of Jammu | 2022 |
| Ph.D | Biological Sciences | CSIR- Indian Institute of Integrative Medicine | 2018 |
| B. Tech | Industrial Biotechnology | Shri Mata Vaishno Devi University | 2012 |
Position Held
| Position Held | Period | Organization |
| Scientist | July 2022 to Present | CSIR-IIIM, Jammu |
| DBT- Senior Research Associate | Jan 2022- July 2022 | University of Jammu |
| DBT- Research Associate | Jan 2020-Dec 2021 | University of Jammu |
Area of Expertise
- Screening of natural compounds and derivatives for anti-inflammatory, anti-rheumatic and anti-obesity potential.
- In vitro cell-based screening of compounds for anti-inflammatory potential using RAW 264.7 and SW982 cells.
- Pre-clinical in-vivo drug mechanistic studies in collagen induced arthritis mice model, LPS-induced sepsis model and high-fat diet induced obesity model.
- Drug-drug interaction including CYP450 inhibition profiling.
- In vivo pharmacokinetic analysis and bioavailability.
Projects
- Mechanism based approach comprising concomitant administration of a natural JAK/STAT inhibitor with leflunomide (DMARD) for the management of adverse drug reactions and improved efficacy in the treatment of rheumatoid arthritis. (DST)
- Isolation, Pharmacopeial Standardization and Immunomodulatory activity of Unani drug Habb-e-suranjan and Habbe-e-Asgand. (CCRAS)
- Pre-IND enabling studies on Adhatoda vasica extracts for treatment of pulmonary fibrosis through hypoxia response modulation.
- (CSIR)Investigation on the anti-obesity activity of Argyreia Nervosa, Garcinia Species. (DBT)
Publications
| Authors | Title | Journal | |
|
Anti-inflammatory and anti-arthritic potential of methotrexate in combination with BA-25, an amino analogue of β-boswellic acid in the treatment of rheumatoid arthritis | Cytokine. 2023 Dec;172:156398 | |
| Iqbal Andrabi N, Sarkar AR, Assim Haq S, Kumar D, Kour D, Saroch D,
Kumar Shukla S, Kumar A, Bhagat A, Ali A, Kour G, Ahmed Z. |
Site-selective synthesis and pharmacological elucidation of novel semi-synthetic analogues of koenimbine as a potential anti-inflammatory agent. | Int Immunopharmacol. 2024 Jan 5;126:111059 | |
| Kour G, Kumar A, Chibber P, Saroch D, Kumar C, Ahmed Z. | Site-selective synthesis and pharmacological elucidation of novel semi-synthetic analogues of koenimbine as a potential anti-inflammatory agent. | Int Immunopharmacol. 2024 Jan 5;126:111059 | |
| Kour G, Haq SA, Bajaj BK, Gupta PN, Ahmed Z. | Novel alantolactone derivative AL-04 exhibits potential anti-inflammatory activity via modulation of iNOS, COX-2 and NF-κB.
|
Cytokine. 2022 Oct;158:155978 | |
| Kour G, Choudhary R, Anjum S, Bhagat A, Bajaj BK, Ahmed Z. | Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future? | Biochemical Pharmacology. 2022, 197:114929.
Impact factor: 6.1 |
|
| Kour G, Singh PP, Bhagat A, Ahmed Z. | Biopharmaceutic parameters, pharmacokinetics, transport and CYP mediated drug interactions of IIIM-017: A novel nitroimidazooxazoleanalogue with anti-tuberculosis activity. | European Journal of Pharmaceutical Sciences. 2017; 106: 71–78.
Impact Factor: 5.1 |
|
| Kour G, Chandan BK, Khullar M, Munagala G, Singh PP, Bhagat A, Gupta AP, Vishwakarma RA, Ahmed Z. | Development and validation of a highly sensitive LCMS/MS-ESI method for quantification of IIIM-019-A novel nitroimidazole derivative with promising action against Tuberculosis: Application to drug development. | Journal of Pharmaceutical and Biomedical Analysis. 2016; 124: 26-33.
Impact Factor: 3.5 |
|
| Kour G, Kumar A, Singh PP, Sharma S, Bhagat A, Vishwakarma RA, Ahmed Z. | Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 – A potential oral treatment for tuberculosis. | Pulmonary Pharmacology and Therapeutics. 2016; 40: 44-51.
Impact Factor: 3.4 |
|
| Kour G, Haq SA, Ahmed Z, Gupta P.N.
|
BookChapter title: Novel delivery systems for natural products in improved therapy of rheumatoid arthritis. Book title: Role and application of novel drug delivery system for phytoconstituents. | CRC Press, 2022
|
|
| Yempalla KR, Munagala G, Singh S, Kour G, Sharma S, Chib R, Kumar S, Wazir P, Singh GD, Raina S, Bharate SS, Khan IA, Vishwakarma RA, Singh PP. | Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents. | ACS Med. Chem. Lett. 2015; 6 (10): 1059-64.
Impact Factor: 4.6
|
Awards and Honours
- Associate Member of the Society of Inflammation Research, India.
- Post-Doctorate Fellowship by the Department of Biotechnology Research Associate (DBT-RA) program in Biotechnology and Life Sciences, Govt. of India (2019)
- Senior Research Fellowship (GATE-SRF) from Council of Scientific and Industrial Research (CSIR), GOI (2014-2017)
- Junior Research Fellowship (GATE-JRF) from Council of Scientific Industrial Research (CSIR), GOI, 2012-2014
- Qualified Jammu and Kashmir State Eligibility Test (JK SET/SLET) in Life Sciences
- QualifiedAll-India Level Examination, Graduate Aptitude Test in Engineering (GATE) in Biotechnology.
- Speaker at International conference: 4th Annual Congress on Drug Discovery & Designing, Bangkok, Thailand, July 03-04, 2017.
- Second Prize in Poster presentation,Indo-US Symposium on Botanical Drug development, Medanta-The Medicity, Gurgaon, India, December 13-14th, 2013.
Students
| Photo | Name | Area of Interest | Position | |
 |
Rupali Choudhary | Investigating the anti-inflammatory and anti-rheumatic potential of natural and semi synthetic compound and their mechanism of action | UGC-SRF | |
 |
Sobia Anjum |
|
UGC-SRF | |
 |
Tazeem Akram | Evaluation of the Anti-inflammatory and anti arthriticpotential of the natural products and their derivatives | CSIR-JRF | |
 |
Arzoo Manzoor | Anti inflammatory and anti arthritic potential of natural products and their derivatives | CSIR-JRF | |
 |
Sweta | Working on investigation of anti-inflammatory potential of natural products and their derivatives | CSIR-JRF |